Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 2137046
PUBLISHER: GlobalData | PRODUCT CODE: 2137046
Narcolepsy: Seven-Market Drug Forecast and Market Analysis 2025-35
PUBLISHED:
PAGES: 96 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
This report covers the 7 major markets and provides an Excel-based forecast model for the narcolepsy market through 2035
The narcolepsy therapeutics market totaled $4.6 billion in 2025 across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan).
It is projected to grow rapidly at 5.5% compound annual growth rate (CAGR) to $7.8 billion by 2035, mainly driven by the entry of orexin agonists from the late-stage pipeline, the introduction of new formulations, and increased treatment rates.
The US has the largest narcolepsy market, accounting for approximately 97% of 7MM sales in 2025 and 2035, due to higher drug prices, the large diagnosed prevalent cases of narcolepsy, and the most products launches during the forecast period.
Scope
- Overview of narcolepsy, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized narcolepsy market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2025 to 2035.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the narcolepsy therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for narcolepsy treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global narcolepsy market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM narcolepsy therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM narcolepsy therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Product Code: GDHCHT769
Table of Contents
Table of Contents
1. Preface
- 1.1. Contents
- 1.2. Abbreviations
- 1.3. Related Reports
2. Executive Summary
3. Narcolepsy Disease Overview
- 3.1. Overview of Narcolepsy
- 3.2. Pathophysiology of Narcolepsy
- 3.3. SWOT Analysis of the Narcolepsy Market
4. Epidemiology
- 4.1. Total Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), Both Sexes, N, All Ages, 2025-35
- 4.2. Diagnosed Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), Both Sexes, N, All Ages, 2025-35
- 4.3. Age-Specific Total Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), N, Both Sexes, All Ages, 2025
- 4.4. Sex-Specific Total Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), N, All Ages, 2025
- 4.5. Trends of Total Prevalence of All Types of Narcolepsy (NT1 and NT2), %, All Ages, Both Sexes, 2015-35
- 4.6. Age-Specific Diagnosed Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), N, Both Sexes, All Ages, 2025
- 4.7. Sex-Specific Diagnosed Prevalent Cases of All Types of Narcolepsy (NT1 and NT2), N, All Ages, 2025
- 4.8. Trends of Diagnosed Prevalence of All Types of Narcolepsy (NT1 and NT2), %, All Ages, Both Sexes, 2015-35
5. Current Treatment Options
- 5.1. Treatment Paradigm
- 5.2. Treatment Pathway by Symptoms for the Management of Adults with Narcolepsy
- 5.3. Current Treatment Options
- 5.4. Product Profile: Jazz Pharmaceuticals' Xyrem (sodium oxybate)
- 5.5. Product Profile: Jazz Pharmaceuticals' Xywav (calcium oxybate + magnesium oxybate + potassium oxybate + sodium oxybate)
- 5.6. Product Profile: Alkermes' Lumryz (sodium oxybate ER)
- 5.7. Product Profile: Teva Pharmaceuticals' Provigil (modafinil)
- 5.8. Product Profile: Teva Pharmaceuticals' Nuvigil (armodafinil)
- 5.9. Product Profile: SK Biopharmaceuticals' Sunosi (solriamfetol)
- 5.10. Product Profile: Bioproject's Wakix (pitolisant)
- 5.11. Product Profile: Bristol-Myers Squibb Ritalin (methylphenidate)
- 5.12. Product Profile: Keenova Therapeutics Methylin (methylphenidate ER)
- 5.13. Product Profile: Sumitomo's Philopon (metamfetamine)
- 5.14. Product Profile: GSK's Dexedrine (dextroamphetamine sulfate ER)
- 5.15. Product Profile: Pemoline
- 5.16. Product Profile: Antidepressants (TCAs, SSRIs, SNRIs)
- 5.17. Product Profile: Takeda's Orzeyful (oveporexton)
- 5.18. Patient Flow - Narcolepsy
6. Unmet Needs and Opportunities
- 6.1. Unmet Needs in Narcolepsy
- 6.2. Addressing the Full Spectrum of Narcolepsy Symptoms
- 6.3. Safer, Non-Scheduled Therapy with No Abuse Burden
- 6.4. Understanding of NT2 Pathophysiology
- 6.5. Disease-Modifying or Curative Approaches for Narcolepsy Patients
- 6.6. Improved Awareness of Narcolepsy
7. R&D Strategies
- 7.1. Trends in Clinical Trial Design in Narcolepsy
- 7.2. Trends in Deal-Making in Narcolepsy
8. Pipeline Assessment
- 8.1. Narcolepsy: Pipeline Overview
- 8.2. Late-Stage Pipeline Agents for Narcolepsy
- 8.3. Product Profile: Takeda's TAK-360
- 8.4. Product Profile: Synchronicity Pharma/Alkermes' alixorexton
- 8.5. Product Profile: Centessa Pharmaceuticals/ Eli Lilly's cleminorexton
- 8.6. Product Profile: pipeline orexin agonists
- 8.7. Product Profile: Suven Life Sciences' samelisant
- 8.8. Product Profile: Harmony Biosciences' pitolisant GR formulation
- 8.9. Product Profile: Harmony Biosciences' pitolisant HD formulation
- 8.10. Product Profile: Axsome Therapeutics' AXS-12 (reboxetine)
- 8.11. Product Profile: Bioron Pharma's BRP-180 (bupropion)
- 8.12. Product Profile: Tris Pharma's TRN-257 (sodium oxybate)
- 8.13. Narcolepsy: Clinical Trials (Phase I/II/III) Overview
9. Market Outlook
- 9.1. Narcolepsy Market Forecast by Country, 2025-35
- 9.2. Narcolepsy Market Forecast by Drug Class, 2025-35
- 9.3. Narcolepsy Market Drivers and Barriers
10. Appendix
- 10.1. Primary Research
- 10.2. Bibliography
- 10.3. About the Authors
11. Contact Us
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.